James R. Johnson

, Marie-Hélène Nicolas-Chanoine, Chitrita DebRoy, Mariana Castanheira, Ari Robicsek, Glen Hansen, Scott Weissman, Carl Urban, Joanne Platell, Darren Trott, George Zhanel, Connie Clabots, Brian D. Johnston, Michael A. Kuskowski, and the MASTER Investigators
Author affiliations: Veterans Affairs Medical Center, Minneapolis, Minnesota, USA (J.R. Johnson, C. Clabots, B.D. Johnston, M.A. Kuskowski); University of Minnesota, Minneapolis (J.R. Johnson, B.D. Johnston, M.A. Kuskowski); Hôpital Beaujon, Clichy, France (M.-H. Nicolas-Chanoine); The Pennsylvania State University, College Park, Pennsylvania, USA (C. DebRoy); JMI Laboratories, North Liberty, Iowa, USA (M. Castanheira); NorthShore University HealthSystem, Evanston, Illinois, USA (A. Robicsek); Hennepin County Medical Center, Minneapolis (G. Hansen); University of Washington, Seattle, Washington, USA (S. Weissman); New York Hospital Queens, Flushing, New York, USA (C. Urban); New York University School of Medicine, New York, New York, USA (C. Urban); University of Queensland, Brisbane, Queensland, Australia (J. Platell); University of Adelaide, Adelaide, South Australia, Australia (D. Trott); University of Manitoba, Winnipeg, Manitoba, Canada (G. Zhanel)
Main Article
Figure

Figure. Prevalence over time of 12 high-prevalence XbaI pulsotypes among 579 Escherichia coli ST131 isolates. High-prevalence pulsotypes are those with >6 isolates (>1% of population) each. Years before 2003 are combined into 3 groups because of the small numbers of isolates. On the x-axis, the number of isolates for the particular period is shown in parentheses below the dates. y-axis prevalence values are based on the total number of isolates in the particular period.
Main Article
Top of Page